Immunosuppressive Therapies

Whenever possible, mRNA COVID-19 vaccination doses (including the primary series and an additional dose) should be completed at least two weeks before initiation or resumption of immunosuppressive therapies, but timing of COVID-19 vaccination should take into consideration current or planned immunosuppressive therapies and optimization of both the patient’s medical condition and response to vaccine.

A patient’s clinical team is best positioned to determine the degree of immune compromise and appropriate timing of vaccination.

 

  infoInterim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States


back
Next


 

Page last reviewed: November 16, 2021